The group inducing hyperprolactinemia with CPZ recorded a significant increase in prolactin, with a decrease in FSH, LH, and progesterone hormones compared to the control group
The result, in animal models and now in human Phase 2 and Phase 3 trials, is not an incremental 1-2 percentage point gain over tirzepatide
Adam Auton, Vice President of Human Genetics at the 23andMe Research Institute said, Identifying these variants in the GLP1R and GIPR genes provides an important new insight into why these medications impact people in distinct ways
This helps us understand your unique needs and determine if peptide therapy is a suitable option
In some trials, early, weight-independent changes point to intrinsic anti-inflammatory actionan appealing feature for vascular brain protection